Heartcore Capital

Teitur Trophics is a biotech company based in Aarhus, Denmark, established in 2020. The company focuses on developing circular peptides aimed at addressing neurodegenerative diseases. By studying small peptides that interact with receptors crucial for neural function, Teitur Trophics aims to understand the underlying biology and modulate key mechanisms involved in neural activity. This research is intended to support healthcare professionals in creating treatments that can prevent the onset of neurodegenerative conditions through daily injections.

Templafy ApS, founded in 2013 and based in Copenhagen, Denmark, provides a comprehensive platform for template and document management solutions. The company specializes in automating business document creation, enabling organizations to produce compliant and on-brand documents efficiently. Its offerings include dynamic personalization, document automation, brand validation, and template governance services. Templafy’s platform integrates seamlessly with existing software, such as Microsoft Office and Salesforce, allowing users to access company templates and streamline content workflows. Catering to various industries, including banking, consulting, education, and legal services, Templafy supports millions of users across over 800 enterprise customers globally. The company has raised significant funding from leading investors to further enhance its innovative document generation capabilities.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Templafy ApS, founded in 2013 and based in Copenhagen, Denmark, provides a comprehensive platform for template and document management solutions. The company specializes in automating business document creation, enabling organizations to produce compliant and on-brand documents efficiently. Its offerings include dynamic personalization, document automation, brand validation, and template governance services. Templafy’s platform integrates seamlessly with existing software, such as Microsoft Office and Salesforce, allowing users to access company templates and streamline content workflows. Catering to various industries, including banking, consulting, education, and legal services, Templafy supports millions of users across over 800 enterprise customers globally. The company has raised significant funding from leading investors to further enhance its innovative document generation capabilities.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Issuu, Inc. is a digital publishing and discovery platform founded in 2006, with headquarters in Palo Alto, California, and additional offices in Berlin and Copenhagen. The company offers a comprehensive suite of tools for digital publishing, allowing users to create and share a variety of content, including magazines, newspapers, catalogs, and portfolios. With a focus on enhancing the reader experience, Issuu supports over 17 million publications and serves more than 80 million active readers each month. The platform enables publishers, both large and small, to easily upload and distribute their work while maintaining the visual appeal associated with print media. Moreover, Issuu provides various features, such as custom viewer themes, API integrations, and monetization solutions, which facilitate seamless publication management and audience engagement across devices and social networks.

Templafy ApS, founded in 2013 and based in Copenhagen, Denmark, provides a comprehensive platform for template and document management solutions. The company specializes in automating business document creation, enabling organizations to produce compliant and on-brand documents efficiently. Its offerings include dynamic personalization, document automation, brand validation, and template governance services. Templafy’s platform integrates seamlessly with existing software, such as Microsoft Office and Salesforce, allowing users to access company templates and streamline content workflows. Catering to various industries, including banking, consulting, education, and legal services, Templafy supports millions of users across over 800 enterprise customers globally. The company has raised significant funding from leading investors to further enhance its innovative document generation capabilities.

FBC Device ApS, founded in 2005 and based in Risskov, Denmark, specializes in the manufacture and marketing of spinal fusion implants. The company achieved its first significant milestone in 2013 when its Statur product line received the CE mark, allowing it to enter the European and Canadian markets. FBC Device has also obtained ISO 13485 certification, reflecting its commitment to high-quality standards. Its innovative two-piece anterior interbody fusion implant incorporates tantalum spheres as radiologic markers, enabling surgeons to adjust lordosis during procedures. This technology aims to improve patient outcomes by offering a self-adapting ALIF cage that positively influences sagittal balance. The company holds patents in Europe and the United States, further solidifying its position in the spinal implant industry.

Mofibo started in Copenhagen (2013) as one of the world’s first book subscription services. We are currently in three countries and will be expanding into more countries within the next 12 months. Our overall goal is to transform the way millions of people interact with books, through using a data-driven and customer centric approach to fundamentally change the reading experience crosses multiple countries.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011 and based in Copenhagen. The company specializes in the development and commercialization of antibiotics aimed at treating multi-drug resistant bacterial infections, particularly those acquired in hospital settings. Its primary focus includes complicated urinary tract infections and hospital or ventilator-acquired pneumonia, which are often caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Adenium Biotech's lead product, Arenicin, is a non-hemolytic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against Gram-negative pathogens. The company operates as a semi-virtual biotech entity, supported by a team of experts and an international scientific advisory board, with the goal of advancing the Arenicin program through clinical development and regulatory filing.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Podio, a collaborative work platform now part of Citrix, offers a unique approach to managing everyday work. It empowers users to customize their work environments by integrating various specialized applications with features such as messaging, task management, reporting, workflow, and contact management. This versatility allows teams to streamline their processes and unify their work activities within a single platform, eliminating the need for multiple tools and logins. Based in Copenhagen, Podio serves a diverse range of teams and organizations globally, providing them with the resources to enhance productivity and collaboration. The company is led by CEO Tommy Ahlers and has a board chaired by Thomas Madsen-Mygdal, with a multinational team that includes members from Germany, France, Britain, and Denmark.

Acarix A/S is a medical technology company specializing in innovative solutions for the rapid exclusion of coronary artery disease (CAD). Established in 2009 as a spin-out from Coloplast A/S, Acarix is rooted in pioneering research initiated at Aalborg University in Denmark. The company has developed the CE-marked CADScor System, which has also received DeNovo approval from the FDA. This system is designed for patients experiencing chest pain with suspected CAD and aims to minimize unnecessary and costly invasive diagnostic procedures. Utilizing advanced acoustics and artificial intelligence, the CADScor System can non-invasively rule out CAD in under 10 minutes, achieving a certainty rate of at least 96 percent. Acarix continues to focus on enhancing patient care and streamlining diagnostic processes in cardiology.

Action Pharma A/S is a biotechnology company focused on research and development, specializing in the discovery and development of novel drugs for cardiovascular, inflammatory, and metabolic diseases. Founded in 2000 and based in Holte, Denmark, the company aims to create treatment options for conditions such as type-II diabetes, obesity, kidney injury related to cardiac surgery, inflammatory bowel disease, rheumatoid arthritis, and inflammatory skin diseases like atopic dermatitis. Its product pipeline includes AP214, a modified MSH peptide analogue for post-surgical kidney injury; AP1030 and AP11 series, oral medications for type-II diabetes; AP1189, an anti-inflammatory compound for various inflammatory diseases; and AP405, another modified MSH peptide aimed at treating inflammatory skin conditions. Action Pharma's approach focuses on targeting melanocortin receptors, progressing its candidates toward clinical proof of concept to facilitate future partnerships.

Action Pharma A/S is a biotechnology company focused on research and development, specializing in the discovery and development of novel drugs for cardiovascular, inflammatory, and metabolic diseases. Founded in 2000 and based in Holte, Denmark, the company aims to create treatment options for conditions such as type-II diabetes, obesity, kidney injury related to cardiac surgery, inflammatory bowel disease, rheumatoid arthritis, and inflammatory skin diseases like atopic dermatitis. Its product pipeline includes AP214, a modified MSH peptide analogue for post-surgical kidney injury; AP1030 and AP11 series, oral medications for type-II diabetes; AP1189, an anti-inflammatory compound for various inflammatory diseases; and AP405, another modified MSH peptide aimed at treating inflammatory skin conditions. Action Pharma's approach focuses on targeting melanocortin receptors, progressing its candidates toward clinical proof of concept to facilitate future partnerships.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Issuu, Inc. is a digital publishing and discovery platform founded in 2006, with headquarters in Palo Alto, California, and additional offices in Berlin and Copenhagen. The company offers a comprehensive suite of tools for digital publishing, allowing users to create and share a variety of content, including magazines, newspapers, catalogs, and portfolios. With a focus on enhancing the reader experience, Issuu supports over 17 million publications and serves more than 80 million active readers each month. The platform enables publishers, both large and small, to easily upload and distribute their work while maintaining the visual appeal associated with print media. Moreover, Issuu provides various features, such as custom viewer themes, API integrations, and monetization solutions, which facilitate seamless publication management and audience engagement across devices and social networks.